BIOGNOSYS
12.10.2021 08:02:08 CEST | Business Wire | Press release
Biognosys, a leader in next-generation proteomics solutions for drug discovery and development, announces today that it is supporting Cancer Scout as Proteomics provider.
Cancer Scout is a large-scale joint research project led by University Medical Center Göttingen and Siemens Healthineers . The project received funding of EUR 10 million by the German Federal Ministry of Education and Research (BMBF) 1 .
The objective of Cancer Scout is to provide a new Artificial Intelligence tool for precision medicine in the fight against cancer . The research project will analyze and combine genomics, proteomics, and pathology data through Artificial Intelligence to generate a "digital biopsy" of molecular changes in tumors. Identifying these molecular changes can support early and accurate cancer diagnosis and predict personalized therapies for a patient’s tumor.
Oliver Rinner, PhD, CEO and founder of Biognosys states: “We are excited to be part of this visionary multi-omics research project and contribute to the development of more personalized clinical diagnostics and therapies for cancer with our proteomics solutions.”
Biognosys was selected as the provider for the Proteomics data analysis in Cancer Scout, based on its unique technologies and workflows for large-scale proteomics, comprehensive quality standards for clinical research, and extensive expertise in precision oncology.
Biognosys’ discovery proteomics platform utilizes proprietary, patented Hyper Reaction Monitoring (HRM™) mass spectrometry technology to quantify complete proteomes with unmatched precision, depth, and reproducibility. This solution can be applied with high throughput in large-scale studies involving thousands of samples from a broad range of clinical sample types.
Professor Philipp Ströbel, Director of Pathology at the University Hospital Göttingen, comments: “ Combining digital pathology with proteomics and other omics data is essential to identify the full spectrum of molecular changes in tumors and enable truly personalized cancer care.”
Christian Wolfrum, Head of New Business Development and Planning at Siemens Healthineers, adds: “We are excited to work with Biognosys to generate novel scientific insights in Cancer Scout and translate these into personalized cancer care solutions for clinical practice.”
About Biognosys
Biognosys is a leader in next-generation proteomics, dedicated to transforming life science by inventing and developing cutting-edge proteomics technology and solutions and making them widely available for pharmaceutical and biotechnology researchers and proteomics experts. The company offers a versatile portfolio of proprietary proteomics services, software, and kits that provide a multi-dimensional view of protein expression, function, and structure in all biological species and sample types. Biognosys’ unique, patented technologies utilize high-resolution mass spectrometry to quantify thousands of proteins across thousands of samples with industry-leading precision, depth, and throughput. Through advanced data analytics, Biognosys translates data into actionable insights for R&D and clinical research. More information at biognosys.com .
About University Hospital Göttingen
The University Medical Center Göttingen (UMG) is one of the leading university medical facilities in Germany. For more information, please visit https://www.umg.eu/en/ .
About Siemens Healthineers
To learn more about Siemens Healthineers, please visit siemens-healthineers.com .
1 Funding reference number FKZ 13GW0451A+B
View source version on businesswire.com: https://www.businesswire.com/news/home/20211011005036/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Digital Trust Index 2026: AI Skepticism and Identity Access Friction Are Costing Revenue31.3.2026 14:00:00 CEST | Press release
93% of IT leaders are deploying GenAI, but only 23% of consumers trust companies that use AI to handle their data. Friction at sign-up, login, and onboarding is causing customer abandonment and revenue loss, with 68% of consumers switching due to website issues. 69% of consumers trust companies more when MFA (multi factor authentication) is used, 68% say the same about passkeys. Thales today released the 2026 Digital Trust Index, one of the most comprehensive global studies of digital trust. Surveying more than 15,000 consumers, business partners, and IT decision makers across 13 industries, the research reveals that digital trust is won or lost during sign-up, login, and throughout the lifecycle of personal data handling. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260331668723/en/ Beyond banking’s clear lead, the rest of the sectors fall well behind in consumer confidence. ©Thales Consumer Trust is Won or Lost at Login
Tanner Pharma Group and Biodexa Launch Global Early Access Program for FAP Patients31.3.2026 14:00:00 CEST | Press release
Tanner Pharma Group, a global provider of specialty medicine access solutions, and Biodexa Pharmaceuticals PLC (Nasdaq: BDRX), a clinical stage biopharmaceutical company developing innovative products for gastrointestinal cancers, have announced a strategic partnership to enable global access to eRapa for patients with Familial Adenomatous Polyposis (FAP) through an Early Access / Named Patient Program. FAP is characterized by a proliferation of polyps in the colon and/or rectum, usually occurring in mid-teens. There is no approved therapeutic option, and surgical resection remains the standard of care. eRapa is a proprietary oral capsule formulation of rapamycin (sirolimus), an mTOR inhibitor involved in cellular metabolism, growth, and proliferation and activated during tumorigenesis. mTOR has been shown to be over-expressed in FAP polyps, supporting the rationale for its use in treatment. Through this collaboration, Tanner Pharma will facilitate compliant, controlled access to eRapa
SLB and Azule Energy Scale Enterprise Digital Operations to Strengthen Energy Delivery in Angola31.3.2026 14:00:00 CEST | Press release
SLB’s enterprise digital platform will enhance execution reliability across Azule’s operations in Angola Global technology company SLB (NYSE: SLB) today announced a three-year agreement with Azule Energy to continue and expand the use of its enterprise digital platform across Azule’s operations in Angola. The platform will help Azule drive more consistent execution, accelerate decision-making, and support reliable energy delivery across its portfolio. Azule Energy — a joint venture of bp and Eni and the largest independent energy producer in Angola — operates some of the region’s most complex assets. The agreement builds on two years of Delfi™ use within Azule’s reservoir organization, where the platform supports reservoir studies, modelling, simulation, and well planning workflows, and supports enterprise-scale digital integration by connecting reservoir workflows with broader operational data environments over time. “Azule operates large, complex energy assets where execution reliabi
Esri and RoboGarden Sign Strategic MOU to Advance Geospatial and Geomatics Education31.3.2026 14:00:00 CEST | Press release
Agreement Explores New Models for Digital Learning, Academic Collaboration, and Global Workforce Readiness Esri and RoboGarden have signed an MOU to explore strategic collaboration that broadens access to modern GIS and geomatics education. RoboGarden, a Canadian EdTech company, offers gamified and scalable digital learning solutions for academic institutions, governments, and industry. The MOU outlines joint exploration of academic pathways, improved regional coordination, and potential creation of a Geospatial & Geomatics Virtual Academy. The agreement focuses on enhancing digital learning delivery, expanding localized e-learning opportunities, and supporting global workforce development in high-demand technology fields. To stay informed about Esri’s education initiatives and resources, visit esri.com/en-us/industries/education/overview. Esri, the global leader in geographic information system (GIS) technology, today announced the signing of a Memorandum of Understanding (MOU) with R
ExaGrid Named a Finalist for the Network Computing Awards 202631.3.2026 14:00:00 CEST | Press release
ExaGrid nominated in 11 Categories for annual industry awards ExaGrid®, the world’s largest independent backup storage vendor providing Tiered Backup Storage with the most Comprehensive Security and AI-Powered Retention Time-Lock for Ransomware Recovery, today announced that it has been nominated in 11 categories for the annual Network Computing Awards. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260331887370/en/ ExaGrid has become a finalist in the following categories: Data Protection Product of the Year The Return On Investment Award Air Gapped Ransomware Recovery Product of the Year Storage Product of the Year Hardware Product of the Year The Customer Service Award Enterprise Product of the Year New Product of the Year Product of the Year Company of the Year Additionally, ExaGrid is nominated for the “Bench Tested Product of the Year” award determined by judges after an independent product review of the ExaGrid Tiered
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom